SCHEMBL6522872

SCHEMBL6522872

COc1ccc(CCc2ccnc3[nH]c(=O)c4ccccc4c23)cc1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTK6 Q13882 1/20 0.50
AURKA O14965 8/20 0.49
AURKB Q96GD4 3/20 0.49
HCAR2 Q8TDS4 1/20 0.46
CYP1A2 P05177 1/20 0.45
CYP3A4 P08684 1/20 0.45
CYP2D6 P10635 1/20 0.45
CYP2C9 P11712 1/20 0.45
CYP2C19 P33261 1/20 0.45
MAPT P10636 2/20 0.44
POLB P06746 1/20 0.43
KDM4E B2RXH2 2/20 0.43
GAA P10253 1/20 0.42
PARP1 P09874 1/20 0.42
ALDH1A1 P00352 1/20 0.41
CCNT1 O60563 1/20 0.41
CCNA2 P20248 1/20 0.41
CDK2 P24941 1/20 0.41
CDK9 P50750 1/20 0.41
QTRT1 Q9BXR0 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6517454 0.88 HCAR2 (0.48) AURKAAURKBHCAR2
SCHEMBL6522914 0.86 AURKA (0.57) AURKAAURKBHCAR2PARP1
SCHEMBL6525271 0.84 EGFR (0.59) PTK6AURKAAURKBMAPTPOLB
SCHEMBL6520671 0.83 AURKA (0.53) PTK6AURKAAURKBHCAR2PARP1
SCHEMBL6519567 0.78 PTK6 (0.54) PTK6AURKAAURKBMAPTKDM4E
SCHEMBL6531042 0.78 MEN1 (0.56) PTK6AURKAAURKBMAPTKDM4E
SCHEMBL6522992 0.78 PTK6 (0.79) PTK6AURKAAURKBKDM4E
SCHEMBL6523257 0.77 AURKA (0.51) AURKAAURKBHCAR2PARP1
SCHEMBL6517875 0.74 PTK6 (0.50) PTK6AURKAAURKBHCAR2MAPT
SCHEMBL6521479 0.73 CDK2 (0.50) AURKAHCAR2CYP1A2CYP3A4CYP2D6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8735584-B2 Protein kinase inhibitors and use thereof MERCK PATENT GMBH (DE) 2014-05-27 US disclosed
US-8735584-B2 Protein kinase inhibitors and use thereof MERCK PATENT GMBH (DE) 2014-05-27 US disclosed
US-8735584-B2 Protein kinase inhibitors and use thereof MERCK PATENT GMBH (DE) 2014-05-27 US disclosed
EP-2254889-B1 PROTEIN KINASE INHIBITORS AND USE THEREOF MERCK PATENT GMBH (DE) 2012-12-19 EP disclosed
EP-2254889-B1 PROTEIN KINASE INHIBITORS AND USE THEREOF MERCK PATENT GMBH (DE) 2012-12-19 EP disclosed
US-20110053906-A1 PROTEIN KINASE INHIBITORS AND USE THEREOF MERCK PATENT GMBH (DE) 2011-03-03 US disclosed
US-20110053906-A1 PROTEIN KINASE INHIBITORS AND USE THEREOF MERCK PATENT GMBH (DE) 2011-03-03 US disclosed
US-20110053906-A1 PROTEIN KINASE INHIBITORS AND USE THEREOF MERCK PATENT GMBH (DE) 2011-03-03 US disclosed
WO-2009108670-A1 PROTEIN KINASE INHIBITORS AND USE THEREOF MERCK SERONO S.A. (CH) 2009-09-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110053906-A1 PROTEIN KINASE INHIBITORS AND USE THEREOF MAP4K2, MAP3K20, MAP4K1 PTK6 186/4885AURKA 538/4885AURKB 487/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.